Immunotherapy for Infectious Diseases

92 Kunert and Katinger
32. Lee S, et al. Enhancement of human immunodeficiency virus type 1 envelope-mediated
fusion by a CD4-gp120 complex-specific monoclonal antibody. J Virol 1997;
71:6037–6043.
33. Abraham E, et al. Double-blind randomised controlled trial of monoclonal antibody to
human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group
[see comments]. Lancet 1998; 351:929–933.
34. Mulligan MS, et al. Inhibition of lung inflammatory reactions in rats by an anti-human
IL-8 antibody. J Immunol 1993; 150:5585–5595.
35. Mündi Y, et al. Inhibition of tumor necrosis factor production and ICAM-1 expression by
pentoxifylline: beneficial effects in sepsis syndrome. Res Exp Med 1995; 195:297–307.
36. Owens R, et al. The in vivo and in vitro characterisation of an engineered human antibody
to E-selectin. Immunotechnology 1997; 3:107–116.
37. Chmel H. Role of monoclonal antibody therapy in the treatment of infectious disease. Am
J Hosp Pharm 1990; 47(11 suppl 3):S11–S15.
38. Chmel H. Monoclonal antibody therapy. Compr Ther 1990; 16:12–16.
39. Finch RG. Design of clinical trials in sepsis: problems and pitfalls. J Antimicrob Chemother
1998; 41(suppl A):95–102.
40. Meissner HC, et al. Safety and pharmacokinetics of an intramuscular monoclonal antibody
(SB 209763) against respiratory syncytial virus (RSV) in infants and young children at
risk for severe RSV disease. Antimicrob Agents Chemother 1999; 43:1183–1188.
41. Meissner HC, et al. Immunoprophylaxis with palivizumab, a humanized respiratory syncytial
virus monoclonal antibody, for prevention of respiratory syncytial virus infection in
high risk infants: a consensus opinion. Pediatr Infect Dis J 1999; 18:223–231.
42. Moore JP, et al. Development of the anti-gp120 antibody response during seroconversion
to human immunodeficiency virus type 1. J Virol 1994; 68:5142–5155.
43. Koup RA, et al. Temporal association of cellular immune responses with the initial control
of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994;
68:4650–4655.
44. Cao Y, et al. Virologic and immunologic characterization of long-term survivors of human
immunodeficiency virus type 1 infection [see comments]. N Engl J Med 1995; 332: 201–208.
45. Mofenson L, Wilfert C. The challenge of HIV infection in infants, children and adolescents.
In: Pediatric AIDS, 3rd ed. Baltimore, MD: Williams & Wilkins, 1998, pp. 487–513.
46. Stoiber H, et al. Inhibition of HIV-1 infection in vitro by monoclonal antibodies to the
complement receptor type 3 (CR3): an accessory role for CR3 during virus entry? Mol
Immunol 1997; 34:855–863.
47. Kostrikis LG, et al. Quantitative analysis of serum neutralization of human immunodeficiency
virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation
between neutralization serotypes and genetic subtypes and evidence for prevalent serumdependent
infectivity enhancement. J Virol 1996; 70:445–458.
48. Muster T, et al. A conserved neutralizing epitope on gp41 of human immunodeficiency
virus type 1. J Virol 1993; 67:6642–6647.
49. Schutten M, et al. Modulation of primary human immunodeficiency virus type 1 envelope
glycoprotein-mediated entry by human antibodies. J Gen Virol 1997; 78:999–1006.
50. Franchini G, et al. Sequence of simian immunodeficiency virus and its relationship to the
human immunodeficiency viruses. Nature 1987; 328:539–543.
51. Dunn CS, et al. High viral load and CD4 lymphopenia in rhesus and cynomolgus macaques
infected by a chimeric primate lentivirus constructed using the env, rev, tat, and vpu genes
from HIV-1 Lai. Virology 1996; 223:351–361.
52. Reimann KA, et al. A chimeric simian/human immunodeficiency virus expressing a primary
patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease
after in vivo passage in rhesus monkeys. J Virol 1996; 70:6922–6928.